Drug Trial Radar · NCT02657330
Study of SBP-101 in Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Apr 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Jan 2016
Primary completion
Oct 2017
Study completion Oct 2017
Sponsor
- Lead sponsor
- Panbela Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD). In addition, this study will also assess the pharmacokinetic (PK) profile and preliminary efficacy of SBP-101.
Conditions
- Pancreatic Cancer
- Ductal Adenocarcinoma of the Pancreas
Interventions
SBP-101Drug
Subcutaneous drug, escalating dose cohorts
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose of SBP-101Time frame: Up to 18 months following the first dose of treatment
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona
Mayo Clinic
Scottsdale, Arizona
Ashford Cancer Centre
Kurralta Park, South Australia, Australia
Austin Hospital
Heidelberg, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.